Biologic therapies

leyendo_libro

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N, Ferrante M, Van Assche G et al. Gastroenterology. 2015 Jun;148(7):1320-9.e3
Estudio Taxit de monitorización de Infliximab en enfermedad inflamatoria intestinal.
Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.
Papamichael K, Gils A, Rutgeerts P et al. Inflamm Bowel Dis. 2015 Jan;21(1):182-97.
Importancia de la monitorizacion de la dosis de carga en enfermedad inflamatoria intestinal.
Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X, Rinaudo M, Del Tedesco E et al. Am J Gastroenterol. 2014 Aug;109(8):1250-6.
Algoritmo de monitorización de adalimumab en enfermedad inflamatoria intestinal.
Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.
A Jamnitski, CL Krieckaert, MT Nurmohamed et al. Ann Rheum Dis. 2012 Jan;71(1):88-91.
Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clin Pharmacokinet. 2010 Aug;49(8):493-507.
Conceptos básicos sobre farmacocinética de Anticuerpos Monoclonales.
Para acceder al artículo pinchar aquí.

PK.GEN